Stroke is a leading cause of death and disability worldwide, and approximately 87% of
cases are attributed to ischemia. The main factors that cause ischemic stroke include …

Neuroprotective and neurorestorative therapy represent two major drug intervention
strategies for ischemic stroke. Multiple factors such as excitotoxicity, inflammation …

Brain injuries resulting from stroke are a major and increasing public health problem in both
developed and developing countries worldwide. China's extensive experience in the use of …

Oxidative/nitrosative stress and neuroinflammation are critical pathological processes in
cerebral ischemia-reperfusion injury, and their intimate interactions mediate neuronal …

Ischemic stroke (IS) is a common neurological disorder associated with high disability rates
and mortality rates. At present, recombinant tissue plasminogen activator (r-tPA) is the only …

Ischemic stroke is a severe cerebrovascular disease with high mortality and morbidity.
Traditional Chinese medicine (TCM) has been utilized for thousands of years in China and …

Ischemic stroke is a challenging disease with high mortality and disability rates, causing a
great economic and social burden worldwide. During ischemic stroke, ionic imbalance and …

Tissue plasminogen activator (t-PA) is the only FDA-approved drug for acute ischemic stroke
treatment, but its clinical use is limited due to the narrow therapeutic time window and …

Ischemic stroke and ischemia/reperfusion (I/R) injury induced by thrombolytic therapy are
conditions with high mortality and serious long-term physical and cognitive disabilities. They …

Stroke is a debilitating disease for which limited therapeutic approaches are available
currently. Thus, there is an urgent need for developing novel therapies for stroke. Astrocytes …